- 596
- 857 772
Certara
United States
Приєднався 3 кві 2012
Certara accelerates medicines using proprietary biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,300 biopharmaceutical companies, academic institutions, and regulatory agencies across 62 countries. For more information, visit www.certara.com.
Відео
Certara's Phoenix Platform
Переглядів 13 години тому
PK/PD analysts. Pharmacometricians. Formulation scientists. They're all rising higher on the wings of the Phoenix Platform. Been a while since you've really explored our solution? From NCA to NLME to IVIVC, get an aerial view of the world's most trusted and versatile PK/PD platform.
Optimising the CYP3A4 Ontogeny in Paediatric PBPK Models - are we there yet?
Переглядів 212 години тому
Topics Covered: • Optimizing Hepatic CYP3A4 ontogeny • Optimizing Intestinal CYP3A4 ontogeny • Using available paediatric clinical data for model verification • Future research Certara accelerates medicines using proprietary biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,300 biopharmaceutical companies, a...
Simcyp In Vitro (Data) Analysis (SIVA) Toolkit for Biopharmaceutics
Переглядів 224 години тому
Topics Covered: • Cyclodextrin binding constants modelling, case study of Itraconazole Certara accelerates medicines to patients using proprietary biosimulation software and technology to transform traditional drug discovery and development. Its clients include 1,600 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 60 countries. Please visit ...
Simulating Cytokine-related Therapeutic Protein - DDI using Simcyp’s TP-Modulator Module
Переглядів 60Місяць тому
Topics Covered: • Introduction to Cytokine-related TP-DDI • Scenario-based Applications • Practical Screen Settings Certara accelerates medicines to patients using proprietary biosimulation software and technology to transform traditional drug discovery and development. Its clients include 1,600 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies acros...
A PBPK Platform Model to Guide Intravenous and Subcutaneous Dosing for Bispecific T Cell Engagers
Переглядів 216Місяць тому
Topics Covered: • Overview of the M-PBPK platform model development for Bispecific T cell engagers • M-PBPK M&S strategies to include ontogeny changes to guide adult and paediatric IV and SC dosing Certara accelerates medicines to patients using proprietary biosimulation software and technology to transform traditional drug discovery and development. Its clients include 1,600 global biopharmace...
Simcyp-R Package
Переглядів 212Місяць тому
Topics Covered: • Brief intro on Simcyp-R package • What is new in the V23 package • Where to get help Certara accelerates medicines to patients using proprietary biosimulation software and technology to transform traditional drug discovery and development. Its clients include 1,600 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 60 countrie...
Certara Talks - ASCPT 2024
Переглядів 542 місяці тому
Certara accelerates medicines to patients using proprietary biosimulation software and technology to transform traditional drug discovery and development. Its clients include 1,600 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 60 countries. Please visit us at www.certara.com/
Certara Talks - Rare Disease Day 2024 Regulatory Landscape
Переглядів 312 місяці тому
Certara accelerates medicines to patients using proprietary biosimulation software and technology to transform traditional drug discovery and development. Its clients include 1,600 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 60 countries. Please visit us at www.certara.com/
Certara Talks - Molecular Glue Development Summit 2024
Переглядів 392 місяці тому
Certara accelerates medicines to patients using proprietary biosimulation software and technology to transform traditional drug discovery and development. Its clients include 1,600 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 60 countries. Please visit us at www.certara.com/
Certara Talks - Rare Disease Day 2024
Переглядів 132 місяці тому
Certara accelerates medicines to patients using proprietary biosimulation software and technology to transform traditional drug discovery and development. Its clients include 1,600 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 60 countries. Please visit us at www.certara.com/
Certara Talks - Rare Disease Day 2024 Clinical Pharmacology
Переглядів 182 місяці тому
Certara accelerates medicines to patients using proprietary biosimulation software and technology to transform traditional drug discovery and development. Its clients include 1,600 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 60 countries. Please visit us at www.certara.com/
Certara Talks - PHUSE 2024
Переглядів 222 місяці тому
Certara accelerates medicines to patients using proprietary biosimulation software and technology to transform traditional drug discovery and development. Its clients include 1,600 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 60 countries. Please visit us at www.certara.com/
PBPK Modelling of Prominent Oral Contraceptive Agents and Applications in DDI
Переглядів 862 місяці тому
Topics Covered: • Simcyp Ethinyl Estradiol model • Development of Progestin models • DDI studies with Oral Contraceptives • Future perspectives Certara accelerates medicines to patients using proprietary biosimulation software and technology to transform traditional drug discovery and development. Its clients include 1,600 global biopharmaceutical companies, leading academic institutions, and k...
Bridging the Gap: Integrating Pharmacometrics w QSP for Smoother Clinical Phase Transitions - Recap
Переглядів 282 місяці тому
Watch the full webinar here: www.certara.com/on-demand-webinar/bridging-the-gap-integrating-pharmacometrics-with-quantitative-systems-pharmacology-qsp-for-smoother-clinical-phase-transitions/?& Certara accelerates medicines to patients using proprietary biosimulation software and technology to transform traditional drug discovery and development. Its clients include 1,600 global biopharmaceutic...
What’s New in the Simcyp™ Simulator - from Regulatory Advances to New Modalities - Recap
Переглядів 232 місяці тому
Watch the full webinar here: www.certara.com/on-demand-webinar/whats-new-in-the-simcyp-simulator-from-regulatory-advances-to-new-modalities/?& Certara accelerates medicines to patients using proprietary biosimulation software and technology to transform traditional drug discovery and development. Its clients include 1,600 global biopharmaceutical companies, leading academic institutions, and ke...
QSP- Enabled FIH Study in Oncology: Saving Clinical Development and Patient Time - Recap
Переглядів 292 місяці тому
QSP- Enabled FIH Study in Oncology: Saving Clinical Development and Patient Time - Recap
How Will Generative AI Take Your Regulatory and Medical Writing Program to the Next Level? - Recap
Переглядів 512 місяці тому
How Will Generative AI Take Your Regulatory and Medical Writing Program to the Next Level? - Recap
Introduction to Simcyp’s Endogenous Biomarker Module
Переглядів 2383 місяці тому
Introduction to Simcyp’s Endogenous Biomarker Module
Impact on the PK of CYP Substrates with Increasing IL-6 after Administration of the TCB, Glofitamab
Переглядів 2204 місяці тому
Impact on the PK of CYP Substrates with Increasing IL-6 after Administration of the TCB, Glofitamab
First-in-Human (FIH) Faster: The Power of Physiologically Based Pharmacokinetic Modeling - Recap
Переглядів 1124 місяці тому
First-in-Human (FIH) Faster: The Power of Physiologically Based Pharmacokinetic Modeling - Recap
Key considerations for simulating oligonucleotides in the Simcyp Simulator
Переглядів 1785 місяців тому
Key considerations for simulating oligonucleotides in the Simcyp Simulator
Certara Talks - JPM Biotech Showcase 2024 Recap
Переглядів 755 місяців тому
Certara Talks - JPM Biotech Showcase 2024 Recap
Setting up a Therapeutic Protein PBPK model in Simcyp Simulator: Key Considerations
Переглядів 2856 місяців тому
Setting up a Therapeutic Protein PBPK model in Simcyp Simulator: Key Considerations
Off-target safety replacing educated guesswork with evidence-based risk assessment
Переглядів 1396 місяців тому
Off-target safety replacing educated guesswork with evidence-based risk assessment
D360 Scientific Informatics Discovery Platform: User Stories
Переглядів 1146 місяців тому
D360 Scientific Informatics Discovery Platform: User Stories
Survival of the Fittest: Evolving Pharmacokinetic Modeling with Pirana
Переглядів 1436 місяців тому
Survival of the Fittest: Evolving Pharmacokinetic Modeling with Pirana
First-In-Human (FIH) faster: The Power of Physiologically Based Pharmacokinetic (PBPK) Modeling
Переглядів 9786 місяців тому
First-In-Human (FIH) faster: The Power of Physiologically Based Pharmacokinetic (PBPK) Modeling
Can ADDL be used in model fit?
Where I can download these demo datasets? Thanks!
Can you say a little bit about how this applies to class I devices, where clinical data may be limited and evaluations based mostly on preclinical data?
37:59 This is a very good way to validate AI, and is the approach I've been using.
32:16 "... create an accurate prompt" is a good point, but my lay person tests have not shown that hallucinations can be avoided.
30:07 - This is a good conversation about how to put AI insights into. Something like "Treat it like a colleagues that has ideas then ask for a justification"
Good job, Ping!
Unfortunately hard to understand
Hi madam,thank you alot,it's very useful information for regulatory personnel.please do upload some other ectd related and things.
Great❤
Many thanks for the vedio
Enjoyable talk! Thanks for sharing!
nice talk. thanks.
INFORMATIVE
Hi .I would like to know what format we need to upload documents..
Great contents!
Very useful. Love the Resident Writer initiative!
Thank you Certara for such an insightful presentation... I hope one-day to be part of your wonderful team of experts.
Excellent content, balanced and well-thought-out responses to questions (which were also top-notch!). The video however was blurred throughout the session (so not an issue with my internet signal quality). Cold this please be rectified?
Your videos are the first thing I watch
please see the updated demo here for version 2, (released Oct 2022); ua-cam.com/video/IA-HbJqOIr8/v-deo.html
How to use downloaded template
any crack version is available ?
فخورة فيك دكتور جعل العلماء والدكاترة السعوديين ❤
where to input the bioavailability data to the model for simulation?
Can get excel sheet data it will be useful for me... For practice purpose..
Please send an email to support@certara.com and we can address your request
Nice job!
Thank you!
updated templates and instruction are available here; www.certarauniversity.com/store/2383230-106-fl-free-phoenix-templates-for-bioequivalence-regulatory-guidances
Working with R via Integral client starts at 30 mins, ua-cam.com/video/UR-5BU_1OH8/v-deo.html
How can we critically appraise Single arm trial ? Which toolkit ? Please suggest
Thanks for sharing viodeo...I am facing issue after close its seems run in background, each time I have to logout windows 10 to again start the application... Could you help with solution
you need to adjust the content
uh
Can we put in a csv file directly for pirahana?
Hi Aditi, I don't quite understand your question, CSVs are of course an acceptable data format. What is in the CSV, source concentrations, run results? Please can you either go to our user forum; support.certara.com/forums/forum/37-pirana-and-rsnlme/ or contact Certara support directly with more details of your question/problem. Thanks, Simon
Wow!! That's amazing
Why did you selected cancer population instead of healthy population while checking the effect of diltizam
1 Bizarre shortcoming of this study: it did not control for baseline anxiety. We know anxiety is positively correlated with severity of covid illness (though we don't know the direction, if there is causality, this is also bizarre, that how 0 "experts" on earth thought to or bothered to do a study exploring this). We know anxiety and covid both affect breathing. We know that fluvoxamine is an SSRI that is used for ocd which is similar to anxiety. So using basic inferential logic and common sense, when a study has 30% efficacy, which is significant but not that high, one would definitely want to check for this confounding variable: could it be that fluvoxamine is partially or mostly reducing the anxiety, which in turn reduces covid severity? This would have a huge implication: it would mean that fluvoxamine would be good for use in those with anxiety, but may not be that useful for others. My guess for why they did not assess for baseline anxiety is because they either didn't think of this common sense confounding variable, or they deliberately ignored it because they thought it would take too much time to properly assess for baseline anxiety, which would require a structured clinical interview and the use of rating scales. However, even if they gave a brief rating scale to participants, or simply asked 1 question like "do you think you were always more anxious than the average person?", given the large sample size, it would have still resulted in some meaningful findings in this regard. But my guess is the journal would have probably rejected their paper if they did this, because they didn't use the "gold standard" method of structured interviews. This is why "scientism" can be counterproductive. Obviously we should aim to use gold standard methods whenever possible, but in a pandemic for example, when there is no time, it makes no sense to completely ignore important variables or completely reject non-gold standard studies when they can result in quick and practical value. Having said all this, given other studies showing the anti inflammatory properties of fluvoxamine and its action in sigma 1 receptors, I would guess that even aside from anxiety it should likely have some benefit against covid. However, it is frustrating that this study did not control for anxiety to more clearly show/prove such an effect.
Pkd disease gene therepy 🤔
Well done Gabby!!
Joshua -- well said, I like the way you emphasized some of the key features and showed the benefits of our Global Submit software!
CovidImages need to be invested more than half19
Demo start around 20 minutes.
Interesting.
Glad you think so!
The video sound is pretty good, beyond my imagination
Is this paid software
Hi Rajni, yes there is a charge for this software. Academics do receive a discount. If you are interested in speaking with someone, please go to www.certara.com and fill out a contact us form, and someone will contact you via email shortly. Thank you!
great presentation
Thank you!
But those people are too young.and are they busy with evidence based information and proof
Plz help me i have rp
The medicine HCQ abbreviation stands for has been blocked by YT. Can’t even talk about it. Censorship!
Please address HCQ treatment in pregnancy